Your browser doesn't support javascript.
loading
Low-grade serous ovarian cancer: expert consensus report on the state of the science.
Grisham, Rachel N; Slomovitz, Brian M; Andrews, Nicole; Banerjee, Susana; Brown, Jubilee; Carey, Mark S; Chui, Herman; Coleman, Robert L; Fader, Amanda N; Gaillard, Stephanie; Gourley, Charlie; Sood, Anil K; Monk, Bradley J; Moore, Kathleen N; Ray-Coquard, Isabelle; Shih, Ie-Ming; Westin, Shannon N; Wong, Kwong-Kwok; Gershenson, David M.
Afiliación
  • Grisham RN; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York, USA grishamr@mskcc.org.
  • Slomovitz BM; Department of Gynecologic Oncology, Mount Sinai Medical Center, Miami Beach, Florida, USA.
  • Andrews N; Florida International University, Miami, Florida, USA.
  • Banerjee S; STAAR Ovarian Cancer Foundation, Western Springs, Illinois, USA.
  • Brown J; The Royal Marsden and the ICR, London, UK.
  • Carey MS; Department of Gynecologic Oncology, Levine Cancer Institute at Atrium Health, Wake Forest University, Charlotte, North Carolina, USA.
  • Chui H; Division of Gynecologic Oncology, Vancouver Coastal Health, Vancouver, British Columbia, Canada.
  • Coleman RL; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Fader AN; Sarah Cannon Research Institute (SCRI), Nashville, Tennessee, USA.
  • Gaillard S; Department of Gynecology and Obstetrics, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
  • Gourley C; Department of Gynecology and Obstetrics, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
  • Sood AK; Cancer Research UK Scotland Centre, University of Edinburgh, Edinburgh, UK.
  • Monk BJ; Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Moore KN; Division of Gynecologic Oncology, Honor Health, University of Arizona, Creighton University, Phoenix, Arizona, USA.
  • Ray-Coquard I; Department of Gynecologic Oncology, Stephenson Cancer Center at the University of Oklahoma Health Sciences, Oklahoma City, Oklahoma, USA.
  • Shih IM; Department of Medical Oncology, Centre Léon Bérard, Lyon, France.
  • Westin SN; Université Claude Bernard Lyon 1, Villeurbanne, France.
  • Wong KK; Department of Gynecology and Obstetrics, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
  • Gershenson DM; Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Int J Gynecol Cancer ; 33(9): 1331-1344, 2023 09 04.
Article en En | MEDLINE | ID: mdl-37591609
ABSTRACT
Compared with high-grade serous carcinoma, low-grade serous carcinoma of the ovary or peritoneum is a less frequent epithelial ovarian cancer type that is poorly sensitive to chemotherapy and affects younger women, many of whom endure years of ineffective treatments and poor quality of life. The pathogenesis of this disease and its management remain incompletely understood. However, recent advances in the molecular characterization of the disease and identification of novel targeted therapies with activity in low-grade serous carcinoma offer the promise of improved outcomes. To update clinicians regarding recent scientific and clinical trial advancements and discuss unanswered questions related to low-grade serous carcinoma diagnosis and treatment, a panel of experts convened for a workshop in October 2022 to develop a consensus document addressing pathology, translational research, epidemiology and risk, clinical management, and ongoing research. In addition, the patient perspective was discussed. The recommendations developed by this expert panel-presented in this consensus document-will guide practitioners in all settings regarding the clinical management of women with low-grade serous carcinoma and discuss future opportunities to improve research and patient care.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Neoplasias Peritoneales / Cistadenocarcinoma Seroso / Cistadenocarcinoma Papilar Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies Límite: Female / Humans Idioma: En Revista: Int J Gynecol Cancer Asunto de la revista: GINECOLOGIA / NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Neoplasias Peritoneales / Cistadenocarcinoma Seroso / Cistadenocarcinoma Papilar Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies Límite: Female / Humans Idioma: En Revista: Int J Gynecol Cancer Asunto de la revista: GINECOLOGIA / NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos